ADMA Biologics Company Insiders
ADMA Stock | USD 20.61 1.90 10.15% |
ADMA Biologics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding ADMA Biologics suggests that vertually all insiders are panicking. ADMA Biologics employs about 15 people. The company is managed by 15 executives with a total tenure of roughly 14 years, averaging almost 0.0 years of service per executive, having 1.0 employees per reported executive.
Adam Grossman CEO President CEO, Director |
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
2024-11-22 | Brad L Tade | Disposed 15000 @ 21.15 | View | ||
2024-09-09 | Lawrence P Guiheen | Disposed 9000 @ 18.47 | View | ||
2024-08-30 | Kaitlin M Kestenberg-Messina | Disposed 24150 @ 16.9 | View | ||
2024-08-29 | Jerrold B Grossman | Disposed 136861 @ 17.27 | View | ||
2024-08-26 | Adam S Grossman | Disposed 236889 @ 17.69 | View | ||
2024-08-23 | Young Kwon | Disposed 60000 @ 18.26 | View | ||
2024-06-14 | Adam S Grossman | Disposed 100000 @ 10.72 | View | ||
2024-03-18 | Steve Elms | Disposed 49887 @ 6.01 | View |
Monitoring ADMA Biologics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
ADMA |
ADMA Biologics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with ADMA Biologics' future performance. Based on our forecasts, it is anticipated that ADMA will maintain a workforce of about 15 employees by April 2025.ADMA Biologics Management Team Effectiveness
The company has return on total asset (ROA) of 0.2124 % which means that it generated a profit of $0.2124 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.8164 %, meaning that it created $0.8164 on every $100 dollars invested by stockholders. ADMA Biologics' management efficiency ratios could be used to measure how well ADMA Biologics manages its routine affairs as well as how well it operates its assets and liabilities. At present, ADMA Biologics' Return On Tangible Assets are projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.42, whereas Return On Capital Employed is forecasted to decline to 0.30. At present, ADMA Biologics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 348 M, whereas Other Assets are forecasted to decline to 1.09.The current year's Common Stock Shares Outstanding is expected to grow to about 255.5 M, whereas Net Loss is forecasted to decline to (62.3 M).
ADMA Biologics Workforce Comparison
ADMA Biologics is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 5,815. ADMA Biologics adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
The company has Profit Margin (PM) of 0.46 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.33 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.33. ADMA Biologics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ADMA Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on ADMA Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ADMA Biologics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2025-03-01 | 2.5714 | 18 | 7 | 1,135,198 | 99,264 |
2024-12-01 | 0.4 | 2 | 5 | 29,011 | 89,164 |
2024-09-01 | 0.6538 | 17 | 26 | 983,756 | 1,729,413 |
2024-06-01 | 0.1176 | 2 | 17 | 492,648 | 723,134 |
2024-03-01 | 0.9333 | 14 | 15 | 1,798,164 | 1,686,482 |
2023-09-01 | 0.6087 | 14 | 23 | 3,064,721 | 7,847,180 |
2023-03-01 | 1.3333 | 16 | 12 | 2,591,270 | 395,406 |
2022-03-01 | 9.5 | 19 | 2 | 2,745,806 | 87,717 |
2021-12-01 | 6.0 | 6 | 1 | 673,500 | 0.00 |
2021-09-01 | 0.4 | 4 | 10 | 2,550,000 | 4,102,427 |
2019-06-01 | 8.0 | 8 | 1 | 4,326,500 | 5,813,954 |
2018-06-01 | 6.5 | 13 | 2 | 260,754 | 17,182,320 |
2017-09-01 | 0.6 | 3 | 5 | 93,006 | 166,264 |
2012-09-01 | 0.5 | 1 | 2 | 13,258 | 0.00 |
2012-06-01 | 6.0 | 6 | 1 | 159,100 | 0.00 |
2012-03-01 | 1.375 | 11 | 8 | 8,998,037 | 486,307 |
ADMA Biologics Notable Stakeholders
An ADMA Biologics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ADMA Biologics often face trade-offs trying to please all of them. ADMA Biologics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ADMA Biologics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Adam Grossman | President CEO, Director | Profile | |
Brian CPA | CFO VP | Profile | |
Brad Tade | CFO Treasurer | Profile | |
CPA CPA | CFO VP | Profile | |
Michael Goldstein | Sr Counsel | Profile | |
Neal Fitzpatrick | Vice Sales | Profile | |
Kaitlin Kestenberg | Project Compliance | Profile | |
Cyndi Tolman | VP Services | Profile | |
Dr DPS | CoFounder Chairman | Profile | |
Skyler Bloom | Senior Strategy | Profile | |
Cindy Petersen | Executive Resources | Profile | |
Drew Pantello | Vice Development | Profile | |
PharmD BCOP | Ex Engagement | Profile | |
John Hafl | Executive Sales | Profile | |
Michael Least | VP Operations | Profile |
About ADMA Biologics Management Performance
The success or failure of an entity such as ADMA Biologics often depends on how effective the management is. ADMA Biologics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ADMA management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ADMA management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.41 | 0.43 | |
Return On Capital Employed | 0.32 | 0.30 | |
Return On Assets | 0.40 | 0.42 | |
Return On Equity | 0.57 | 0.54 |
Please note, the presentation of ADMA Biologics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ADMA Biologics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of ADMA Biologics' management manipulating its earnings.
ADMA Biologics Workforce Analysis
Traditionally, organizations such as ADMA Biologics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ADMA Biologics within its industry.ADMA Biologics Manpower Efficiency
Return on ADMA Biologics Manpower
Revenue Per Employee | 28.4M | |
Revenue Per Executive | 28.4M | |
Net Loss Per Employee | 1.9M | |
Net Loss Per Executive | 1.9M | |
Working Capital Per Employee | 13.8M | |
Working Capital Per Executive | 13.8M |
Complementary Tools for ADMA Stock analysis
When running ADMA Biologics' price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |